Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
1.30% $0.780
America/New_York / 28 jun 2023 @ 15:48
FUNDAMENTALS | |
---|---|
MarketCap: | 47.38 mill |
EPS: | -0.0100 |
P/E: | -78.00 |
Earnings Date: | Apr 26, 2023 |
SharesOutstanding: | 60.75 mill |
Avg Daily Volume: | 0.149 mill |
RATING 2023-06-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | |||||
Asset | n/a | n/a | n/a | n/a | n/a | |
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -78.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-13.27x |
Company: PE -78.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.672 - 0.888 ( +/- 13.85%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.780 (1.30% ) |
Volume | 0.0032 mill |
Avg. Vol. | 0.149 mill |
% of Avg. Vol | 2.16 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.